Polyrizon (PLRZ) Competitors $1.57 -0.76 (-32.62%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends PLRZ vs. MRNS, NERV, TRAW, JAGX, ACXP, HCWB, CARA, TXMD, NRXP, and SLGLShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include Marinus Pharmaceuticals (MRNS), Minerva Neurosciences (NERV), Traws Pharma (TRAW), Jaguar Health (JAGX), Acurx Pharmaceuticals (ACXP), HCW Biologics (HCWB), Cara Therapeutics (CARA), TherapeuticsMD (TXMD), NRx Pharmaceuticals (NRXP), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical preparations" industry. Polyrizon vs. Marinus Pharmaceuticals Minerva Neurosciences Traws Pharma Jaguar Health Acurx Pharmaceuticals HCW Biologics Cara Therapeutics TherapeuticsMD NRx Pharmaceuticals Sol-Gel Technologies Polyrizon (NASDAQ:PLRZ) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations. Does the MarketBeat Community favor PLRZ or MRNS? Marinus Pharmaceuticals received 437 more outperform votes than Polyrizon when rated by MarketBeat users. CompanyUnderperformOutperformPolyrizonN/AN/AMarinus PharmaceuticalsOutperform Votes43767.54% Underperform Votes21032.46% Is PLRZ or MRNS more profitable? Polyrizon has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. Polyrizon's return on equity of 0.00% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets PolyrizonN/A N/A N/A Marinus Pharmaceuticals -446.48%-7,831.35%-120.74% Which has higher valuation and earnings, PLRZ or MRNS? Polyrizon has higher earnings, but lower revenue than Marinus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyrizonN/AN/AN/AN/AN/AMarinus Pharmaceuticals$30.99M0.41-$141.40M-$2.47-0.09 Do analysts rate PLRZ or MRNS? Marinus Pharmaceuticals has a consensus target price of $4.79, suggesting a potential upside of 1,980.75%. Given Marinus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Polyrizon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Marinus Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Do institutionals and insiders believe in PLRZ or MRNS? 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. 5.5% of Marinus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer PLRZ or MRNS? In the previous week, Polyrizon had 6 more articles in the media than Marinus Pharmaceuticals. MarketBeat recorded 7 mentions for Polyrizon and 1 mentions for Marinus Pharmaceuticals. Polyrizon's average media sentiment score of 0.37 beat Marinus Pharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Marinus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryMarinus Pharmaceuticals beats Polyrizon on 8 of the 13 factors compared between the two stocks. Ad Stansberry ResearchThis is the worst sign for the U.S. stock market in 50 yearsThe Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone" Click here to see Dan's new, urgent warning about the U.S. market for 2025. Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.59M$6.57B$5.15B$9.08BDividend YieldN/A2.99%5.12%4.24%P/E RatioN/A10.5086.8817.14Price / SalesN/A196.061,116.56117.12Price / CashN/A57.1643.2337.85Price / BookN/A5.094.794.78Net IncomeN/A$151.83M$120.55M$225.60M7 Day Performance58.43%-2.14%-1.92%-1.23%1 Month PerformanceN/A-4.56%13.67%0.46%1 Year PerformanceN/A8.87%28.47%15.24% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$1.57-32.6%N/AN/A$6.59MN/A0.00N/ANews CoverageGap DownMRNSMarinus Pharmaceuticals4.3188 of 5 stars$0.29+3.6%$4.79+1,568.7%-97.6%$15.83M$30.99M-0.11110Analyst ForecastNews CoverageNERVMinerva Neurosciences3.4706 of 5 stars$2.21-5.6%$5.00+126.2%-67.0%$15.45MN/A-5.349Analyst ForecastNews CoveragePositive NewsGap DownTRAWTraws PharmaN/A$5.01-2.7%N/AN/A$15.18M$230,000.00-0.0317Positive NewsGap DownJAGXJaguar Health0.2612 of 5 stars$1.28+29.3%N/A-89.9%$15.10M$9.76M0.0050News CoverageGap UpHigh Trading VolumeACXPAcurx Pharmaceuticals1.378 of 5 stars$0.88-5.0%$12.00+1,259.6%-77.0%$14.91MN/A-0.853Gap UpHCWBHCW Biologics0.4081 of 5 stars$0.39-3.3%N/A-60.4%$14.74M$3.50M-0.4040Gap DownCARACara Therapeutics4.2348 of 5 stars$0.27-2.0%$2.32+768.9%-29.0%$14.65M$20.97M-0.1655News CoverageGap DownTXMDTherapeuticsMD0.4357 of 5 stars$1.25-0.8%N/A-53.8%$14.41M$1.30M0.00420Analyst ForecastNRXPNRx Pharmaceuticals3.3034 of 5 stars$1.19-1.7%$32.00+2,589.1%-96.5%$14.39MN/A-0.572News CoveragePositive NewsSLGLSol-Gel Technologies2.4195 of 5 stars$0.51flat$5.00+878.7%-66.5%$14.23M$1.55M-1.5350 Related Companies and Tools Related Companies Marinus Pharmaceuticals Alternatives Minerva Neurosciences Alternatives Traws Pharma Alternatives Jaguar Health Alternatives Acurx Pharmaceuticals Alternatives HCW Biologics Alternatives Cara Therapeutics Alternatives TherapeuticsMD Alternatives NRx Pharmaceuticals Alternatives Sol-Gel Technologies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PLRZ) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLRZ Stock Alerts